Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver

NCT ID: NCT03151213

Last Updated: 2018-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aimed to investigate the preemptive analgesia efficacy of of preemptive pregabalin for the postoperative pain management after radiofrequency ablation (RFA) of liver cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our data will investigate if preemptive administration of pregabalin will have a role in reducing postoperative pain after radiofrequency ablation (RFA) of liver cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers
Double blinded by closed envelops

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregabalin

Pregabalin 150 mg before intervention

Group Type ACTIVE_COMPARATOR

Pregabalin 150mg

Intervention Type DRUG

Pregabalin 150mg before RFA of liver cancer

Placebo

Placebo before intervention

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo before RFA of liver cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin 150mg

Pregabalin 150mg before RFA of liver cancer

Intervention Type DRUG

Placebo

Placebo before RFA of liver cancer

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pregab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HCC patients, Child A, B, scheduled for Radiofrequency ablation of HCC.

Exclusion Criteria

* Encephalopathy, Renal impairment
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sherief Abd-Elsalam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sherief Abd-Elsalam

PhDTropical Medicine

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amr Magdy Abdelfattah, consultant

Role: PRINCIPAL_INVESTIGATOR

Tanta University Faculty of Medicine

Sherief Abd-Elsalam, Consultant

Role: STUDY_DIRECTOR

Tanta university Faculty of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta university - faculty of medicine

Cairo, Elgharbia, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sherief Abd-Elsalam, consultant

Role: CONTACT

00201095159522

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sherief Abdelsalam, lecturer

Role: primary

00201095159522

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

amr magdy

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.